Monoclonal antibodies - A new era in the treatment of multiple myeloma.

[1]  A. Palumbo,et al.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. , 2015, The New England journal of medicine.

[2]  Jessica Katz,et al.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. , 2015, The New England journal of medicine.

[3]  P. Richardson,et al.  Promising therapies in multiple myeloma. , 2015, Blood.

[4]  P. Sonneveld,et al.  Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma , 2015, Expert review of hematology.

[5]  M. Caligiuri,et al.  A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma , 2015, Clinical Cancer Research.

[6]  A. Krishnan,et al.  Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Jakubowiak,et al.  A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). , 2015 .

[8]  M. Dimopoulos,et al.  ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). , 2015 .

[9]  G. Salles,et al.  A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL). , 2015 .

[10]  R. Pazdur,et al.  FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease , 2015, Clinical Cancer Research.

[11]  E. Tsiridis,et al.  Treatment of multiple myeloma bone disease: experimental and clinical data , 2015, Expert opinion on biological therapy.

[12]  M. Dimopoulos,et al.  A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma , 2015, American journal of hematology.

[13]  S. Jagannath,et al.  Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma , 2014 .

[14]  S. Jagannath,et al.  Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib , 2014 .

[15]  N. Munshi,et al.  A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events , 2014, British journal of haematology.

[16]  A. Palumbo,et al.  Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. , 2014, Blood.

[17]  P. Richardson,et al.  Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. , 2014 .

[18]  K. Anderson,et al.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. , 2014, Blood.

[19]  J. Laubach,et al.  Daratumumab granted breakthrough drug status , 2014, Expert opinion on investigational drugs.

[20]  D. Esseltine,et al.  A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. , 2014, Blood.

[21]  Cesar Libanati,et al.  Romosozumab in postmenopausal women with low bone mineral density , 2014, The New England journal of medicine.

[22]  Michael L. Wang,et al.  Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. , 2013, Blood.

[23]  Don M. Benson,et al.  Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC , 2013, Cancer Immunology, Immunotherapy.

[24]  H. Goldschmidt,et al.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[25]  H. Lokhorst,et al.  New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients , 2013, Expert opinion on pharmacotherapy.

[26]  N. Raje,et al.  Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study. , 2013 .

[27]  J. Laubach,et al.  Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. , 2013 .

[28]  P. Sonneveld,et al.  A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma , 2013, British journal of haematology.

[29]  G. Roodman,et al.  Myeloma bone disease: Pathophysiology and management , 2013, Journal of bone oncology.

[30]  P. Richardson,et al.  Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study , 2012 .

[31]  F. Saad,et al.  Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. , 2012, European journal of cancer.

[32]  Michael L. Wang,et al.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. , 2012, Blood.

[33]  T. Izumi.  [Management of bone disease in multiple myeloma]. , 2012, Gan to kagaku ryoho. Cancer & chemotherapy.

[34]  J. Teillaud.  Antibody‐dependent Cellular Cytotoxicity (ADCC) , 2012 .

[35]  A. Jakubowiak,et al.  Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Jagannath,et al.  Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  H. Goldschmidt,et al.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.

[38]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[39]  G. Roodman,et al.  Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. , 2011, Blood.

[40]  P. Parren,et al.  The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies , 2011, Blood cancer journal.

[41]  J. San-Miguel,et al.  Can multiple myeloma become a curable disease? , 2011, Haematologica.

[42]  A. Chanan-Khan,et al.  Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Kenneth C. Anderson,et al.  Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors , 2011, The Journal of Immunology.

[45]  S. Jagannath,et al.  Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis , 2010 .

[46]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[47]  R. Vij,et al.  An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma , 2009, American journal of hematology.

[48]  D. Kuhn,et al.  Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death , 2009, British journal of haematology.

[49]  X. Mariette,et al.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Kostenuik,et al.  Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  N. Munshi,et al.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.

[52]  Yuankai Shi,et al.  Immunophenotypic study of basophils by multiparameter flow cytometry. , 2008, Archives of pathology & laboratory medicine.

[53]  F. Zhan,et al.  CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma , 2008, Clinical Cancer Research.

[54]  B. Barlogie,et al.  Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. , 2008, Blood.

[55]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[56]  N. Munshi,et al.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. , 2007, Blood.

[57]  N. Wake,et al.  CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls. , 2007, Gynecologic oncology.

[58]  Diane Warren,et al.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.

[59]  M. Dimopoulos,et al.  Serum concentrations of Dickkopf‐1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation , 2006, International journal of cancer.

[60]  J. Body,et al.  A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[62]  D. Carrasco,et al.  In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells , 2004, Cancer Research.

[63]  G. Tricot,et al.  Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. , 2004, American journal of clinical pathology.

[64]  J. Rossi,et al.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  R. Ohno,et al.  Clinicopathological and prognostic characteristics of CD56‐negative multiple myeloma , 2002, British journal of haematology.

[66]  U. Dianzani,et al.  Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. , 2002, Blood.

[67]  G. Morgan,et al.  The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. , 2000, Blood.

[68]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[69]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[70]  I. Rensink,et al.  Chimaeric anti‐interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose‐escalating study , 1998, British journal of haematology.

[71]  R. Bataille,et al.  The gp 130 family cytokines IL‐6, LIF and OSM but not IL‐11 can reverse the anti‐proliferative effect of dexamethasone on human myeloma cells , 1995, British journal of haematology.

[72]  F. Malavasi,et al.  Human CD38: a glycoprotein in search of a function. , 1994, Immunology today.

[73]  R. Testi,et al.  Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule , 1989, The Journal of experimental medicine.

[74]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[75]  M. Cooper,et al.  Discontinuous expression of a membrane antigen (HB-7) during B lymphocyte differentiation. , 1984, Tissue antigens.

[76]  G A Howie,et al.  Antimitotic activity of the potent tumor inhibitor maytansine. , 1975, Science.

[77]  J. Berdeja.  Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. , 2014, Frontiers in bioscience.

[78]  S. Rajkumar.  CME Information: Multiple Myeloma: 2014 update on diagnosis, risk-stratification and management , 2014 .

[79]  J. Shah,et al.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) , 2014, Leukemia.

[80]  M. Caligiuri,et al.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. , 2012, Blood.

[81]  P. Tassone,et al.  HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. , 2005, Blood.

[82]  S. Deaglio,et al.  Human CD38: a (r)evolutionary story of enzymes and receptors. , 2001, Leukemia research.

[83]  J. Geffner.  Antibody-Dependent Cellular Cytotoxicity , 1998 .

[84]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.

[85]  S. Singhal,et al.  A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. , 2012, Blood.